Serum lipidomics analysis in non-obese and obese patients with non-alcoholic fatty liver disease

Abstract

Abstract: Objective To compare the serum lipid profiles between non obese and obese patients with non-alcoholic fatty liver disease (NAFLD) patients. Methods A total of 60 NAFLD patients were recruited and categorized into two groups based on body mass index(BMI): non-obese (BMI<25 kg/m²) and obese (BMI ≥ 25 kg/m²) . Serum samples from all patients were analyzed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) for lipidomics profiling. Differential lipids were identified through multiple statistical methods, including fold change anaysis, partial least squares discriminant analysis (PLS-DA), and orthogonal partial least squares discriminant analysis (OPLS-DA). Permutation tests were conducted to validate the results. Results A total of 90 differential lipids were identified, Including sphingomyelin (SM), Ether linked phosphatidylcholine (EtherPC), hexosylceramides (HexCer), and phosphatidylethanolamine(PC). KEGG pathway enrichment analysis revealed significant alterations in several metabolic pathways in non-obese NAFLD patients, such as the sphingolipid signaling pathway, necroptosis, glycerophospholipid metabolism pathway, glycosylphosphatidylinositol biosynthetic pathway, and tumor choline metabolism pathway. Conclusion Significant differences in serum lipid mass spectrometry profiles were observed between non-obese and obese NAFLD patients, particularly in PC, PE, SM levels.

Key words: Non-alcoholic fatty liver disease, Lipidomics, Obese

DING Rong-rong, ZHOU Xin-lan, LI Xiu-fen, HUANG Dan, LIN Wei-jia, CHEN Liang. Serum lipidomics analysis in non-obese and obese patients with non-alcoholic fatty liver disease[J]. Chinese Hepatolgy, 2024, 29(8): 975-979.

References 14

[1]	Feng RN, Du SS, Wang C, et al. Lean-alcoholic fatty liver disease risk for metabolic disorders in a nomal weight Chinese population [J]. World J Gastroenterol,2014,20(47):17932-40.
[2]	Leung JC,Loong TC,Wei JL,et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology,2017,65(1):54-64.
[3]	Cusi K.Nonalcoholic steatohepatiti8 in nonobese patients:not so different after all[J]. Hepatology,2017,65(1):4-7.
[4]	Han X. Lipidomics for studying metabolismJ [J]. Nat Rev Endocrinol, 2016,12(11) :668-680.
[5]	中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].实用肝脏病杂志,2018,21:177-186.
[6]	Tan EX, Lee JW, Jumat NH, et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study [J]. Metabolism,2022,126:154911.
[7]	Chiappini F, Coilly A, Kadar H, et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients [J]. Sci Rep, 2017, 24(7):46658.
[8]	Loomba R, Quehenberger O, Armando A, et al. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis [J]. J Lipid Res, 2015, 56(1):185-192.
[9]	Jung Y,Lee MK,Puri P,et al.Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease [J]. Aliment Pharmacol Ther,2020,52(10):1603-1614.
[10]	Veen JN, Kennelly JP, Wan S, et al. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease [J]. Biochim Biophys Acta Biomembr, 2017,1859(9 Pt B):1558-1572.
[11]	曾钗明 , 陈建康 , 李兴华等. 慢性乙型肝炎合并非酒精性脂肪肝的临床和实验室特征 [J]. 中国医学创新 , 2019, 16(35): 136-141.
[12]	Puri P,Baillie RA,Wiest MM,et al.A lipidomic analysis of nonalcoholic fatty liver disease [J]. Hepatology,2007,46(4):1081-1090.
[13]	Chew WS, Torta F, Ji S, et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence [J]. JCI Insight,2019,5(13):e126925.
[14]	Tu LN, Showalter MR, Cajka T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice [J]. Sci Rep,2017,7(1):6120.

[1]	PENG Yu-han, LIU Zi-lan, ZHANG Xiao. Clinical study of dulaglutide combined with a ketogenic diet in the treatment of elderly patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease [J]. Chinese Hepatolgy, 2024, 29(9): 1132-1136.
[2]	GE Yu, WANG Chao-qun, CHEN Yi, SHEN Ruo-yu, DONG Xu. Association between serum uric acid-to-creatinine ratio and metabolic associated fatty liver disease in non-obese patients [J]. Chinese Hepatolgy, 2024, 29(8): 985-989.
[3]	QIAN Xiao-jing, CHEN Ying, LIU Wang zhen-zu, ZHANG Jia-qi, JIANG Yuan-ye, HU Cheng. Effect of an isocaloric high-protein low-carbohydrate diet on serum lipid profile in nonalcoholic fatty liver disease [J]. Chinese Hepatolgy, 2024, 29(6): 706-713.
[4]	ZHAO Dong-zhi, LI Guo-dong, CHANG Yuan-yuan, CAO Zhe-li, ZHAO Ya-juan. Correlation between C/RL-r, APRI, FIB-4 levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease [J]. Chinese Hepatolgy, 2024, 29(1): 68-72.
[5]	ZHANG Si-min, YUAN Yi-fu, WU Xiao-xi, DU Sheng-nan, CAO Qin, JIANG Yuan-ye. Clinical characteristics of non-alcoholic fatty liver disease patients with concurrent acute drug-induced liver injury across varied age cohorts [J]. Chinese Hepatolgy, 2023, 28(9): 1088-1092.
[6]	ZHANG Si-min, DU Shen-nan, YUAN Yi-fu, HE Shi-jia, CAO Qin, JIANG Yuan-ye. The clinical characterization and serum lipidomic analysis of lean nonalcoholic fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(7): 799-805.
[7]	LI Hong-lin, DENG Quan-min. The clinical significance of the alteration of serum 25(OH)D levels in obese children with nonalcoholic fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(7): 810-813.
[8]	LI Wan, HAN Yan-xia, XIE Shou-zhen, MA Ying-cai, YANG Yong-geng, LI Ping-ying. The impact of weight loss on the severity of liver fibrosis and fatty liver in patients with chronic hepatitis B and/or non-alcoholic fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(2): 203-206.
[9]	HU Zhao-suo, YAO Chun-yan, JIN Juan, YAN Bo, CHEN Zheng-xu. Correlation between non-alcoholic fatty liver disease, Helicobacter pylori infection, and the incidence of colorectal polyps [J]. Chinese Hepatolgy, 2023, 28(12): 1472-1475.
[10]	LIU Xi, SHU Chang. Combined effects of vitamin D and probiotics on nonalcoholic fatty liver disease in obese pediatric patients [J]. Chinese Hepatolgy, 2023, 28(11): 1351-1355.
[11]	YANG Cheng, YANG Hua-sheng, HU Jian-hua, ZHANG Li-li, XU Chen. Visualized analysis on the association of nutrition with end-stage liver disease [J]. Chinese Hepatolgy, 2023, 28(1): 65-69.
[12]	LU Jia-hui, ZHANG Cong-nan, HE Peng-yuan, OU Meng-dang, HUANG Ming-xing. Efficacy and safety of tenofovir alafenamide fumarate in the treatment of CHB patients complicated with fatty liver disease [J]. Chinese Hepatolgy, 2022, 27(8): 858-862.
[13]	XU Zi-xin, LIAO Hong-yu, LI Hui-yi, XU Ming-yi. The effect of microRNA-219 on lipid metabolism, cell viability and apoptosis of hepatocytes under lipotoxic environment [J]. Chinese Hepatolgy, 2022, 27(8): 920-924.
[14]	WANG Tie-gang, LI Xiao-ming, ZHU Dan-yang. MRI proton density and fat fraction in non-obese NAFLD patients with different liver histological characteristics [J]. Chinese Hepatolgy, 2022, 27(5): 573-575.
[15]	FENG Dan-ni, ZHANG Da-li, HE Xi, ZHANG Xiao-feng, NIU Xiao-feng, LI Zhi-jie, LI Li-xin, LIU Jia, ZHUANG Yun-long, LIU Zhen-wen, WANG Hong-bo. The case-control study of the association between pre-alcoholic cirrhosis and new-onset non-alcoholic fatty liver disease after liver transplantation [J]. Chinese Hepatolgy, 2022, 27(1): 95-97.